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A B S T R A C T   
Resveratrol, a natural polyphenolic ingredient extracted from herbs, suppresses oxidative stress and inflamma-
tion. We performed a comprehensive review to find any evidence about the effects of Resveratrol on acute 
pancreatitis (AP). Resveratrol has been found to directly impact cytokine generation. As these factors play a 
crucial role in the pathophysiology of AP, resveratrol might attenuate AP and its complications. Mechanistically, 
resveratrol exerts its pharmacological effects through anti-inflammatory and antioxidant mechanisms via 
interaction with different signaling molecules and transcription factors. Indeed, resveratrol might prove to be an 
effective therapeutic component for AP treatment in the future. In this review, we shed light on potential most 
recent pathways through which resveratrol might impact the management and control of AP.   
1. Introduction 
Acute pancreatitis (AP) is a severe inflammation of the pancreas 
causing enzyme activation inside the pancreas, triggering auto- 
degradation accompanied by local and systemic inflammation [1]. The 
prevalence of AP is increasing worldwide [2]. Despite advances in di-
agnostics and treatment, AP is still associated with both severe 
morbidity and mortality [3]. Multiple factors may be involved in the 
pathogenesis of AP, e.g., alcohol consumption or bile duct obstruction. If 
causal factors are taken care off immediately, both the pancreatic 
structure and activity can recover to normal. Still, AP may become a 
life-threatening condition [4]. For instance, severe AP can alter the 
function and structure of the pancreatic duct and eventually cause 
chronic obstructive pancreatitis [5]. Current state-of-the-art care of AP 
mainly consists of supportive care including monitoring vital signs and 
arterial oxygen saturation, hydration, and analgesic treatment [6]. 
Resveratrol (3,5,40-trihydroxy-transstilbene), a well-known tradi-
tional medicine, it is a polyphenol rich ingredient extracted from several 
plants [7]. The highest concentration of resveratrol (50− 100 μg/g) is 
found in grape skins [8,9]. Resveratrol is usually found in herbs in 
trans-resveratrol form, and when orally consumed, trans-resveratrol is 
quickly transformed to the biologically more active form of 
dihydro-resveratrol (Fig. 1) [10]. Resveratrol has several biological 
properties, e.g., it inhibits platelet aggregation [11] and exerts 
anti-inflammatory, chemopreventive and antioxidant effects [12]. 
Because of its wide range of pharmacological effects and easy methods 
of extraction, resveratrol has been used in the management of a lot of 
diseases and received an increasing amount of attention in recent years 
[13]. It has been shown in previous studies that supplementation of 
resveratrol has an effect on proinflammatory cytokines, hyperglycemia, 
and antioxidant competence and protects β-cell ultrastructure [14]. 
Benefits of resveratrol in the management of AP have been suggested 
because of its antioxidant, anti-inflammatory, and immunomodulatory 
functions [15]. Resveratrol exerts its effects through modulation of 
several metabolic factors, transcriptional elements, and miRNAs (Fig. 2). 
AP is often accompanied by a systemic inflammatory response syn-
drome due to an elevation of inflammatory mediators requiring urgent 
management [16,17]. Resveratrol has antioxidative and 
anti-coagulative and immunomodulatory properties, all of which may 
alleviate AP. The aim of this review was to summarize the most recent 
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findings about the effects of resveratrol on AP. 
1.1. Antioxidant effects of resveratrol 
Histopathological results showed that treatment with resveratrol 
preserves the pancreatic acinar cells from degeneration, leukocyte 
infiltration and edema in rats [18–20]. There is growing evidence 
indicating the pivotal role of free radicals in the pathophysiology of 
several inflammatory conditions, including AP [21]. It has been shown 
that oxidative stress is one main reason for acinar cell damage in 
experimental AP [22]. Moreover, it seems that ROS cause increasing 
pain in patients suffering from AP [23]. Recent findings indicate that AP 
causes a decrease of strength in the antioxidant defense system, for 
instance, it has been shown that total antioxidant status (TAS) is 
decreased in AP patients. Interestingly, research has shown that 
resveratrol can restore the TAS to normal levels in AP patients [24]. It 
has been reported that oral administration of resveratrol significantly 
inhibits glutathione depletion in cerulein-induced AP rats [25,26]. 
As AP causes an oxidative alteration of proteins, elevation of the 
amount of 2,4-dinitrophenylhydrazine (DNPH)-reactive protein car-
bonyls was observed in the pancreatic tissue of AP rats [27,28]. In-
terventions with resveratrol were shown to significantly diminish 
irreversible carbonylation of proteins during AP [29,30]. In addition, 
some studies showed that resveratrol restored Plasma glutathione 
peroxidase (GSH-Px) concentrations and reduced lipid peroxidation in 
the pancreas [20,31,32]. Lipid peroxidation leads to increased damage 
in lipid membranes, such as those of zymogen granules in the pancreas 
[33,34]. Malondialdehyde (MDA)is the degraded organic compound of 
lipid peroxidation which is generated when unsaturated fatty acids of 
cell membranes are attacked by ROS, consequently, MDA concentrations 
can reliably and indirectly indicate the level of lipid peroxidation in 
tissues [35]. There are several studies which indicate that resveratrol 
significantly reduced MDA levels in AP patients, proposing that resver-
atrol efficiently suppresses lipid peroxidation [25,36]. Resveratrol 
consumption has protective effects on the gastrointestinal mucosa, 
possibly due to its antioxidant activities and radical scavenging. This is 
probably a major mechanism of resveratrol against gastrointestinal in-
juries caused by AP. Superoxide dismutase (SOD) is another antioxidant 
enzyme which can decrease oxidative stress and inflammatory activity 
[37]. Resveratrol has been shown to increase SOD levels in several 
studies [38,39]. In addition, resveratrol has effects on other mediators of 
oxidative stress such as Nitric oxide (NO) and Myeloperoxidase (MPO). 
NO is present in several physiological processes such as neurotrans-
mission, inflammation and modulation of vascular tone. For instance, 
resveratrol has been shown to have a cardioprotective effect by 
elevating the generation of endothelial Nitric oxide synthase (eNOS) 
[40], inducible nitric oxide synthase (iNOS) [41] and NO [42]. How-
ever, other studies found that resveratrol decreased the expression of 
iNOS and NO [43,44]. Although the true function of NO in the patho-
physiology of AP has not been totally understood, eNOS has been 
demonstrated to have a protective impact by elevating the pancreatic 
blood flow rate [45]. At the same time, however, iNOS also shows 
pro-inflammatory functions [46], and it has been shown that serum 
concentrations of NO are associated with increasing severity and mor-
tality from AP in randomized clinical trials [47]. 
The production of superoxide anion, catalysed by NADPH oxidase, is 
increased as one of the main outcomes of oxidative stress [48]. It has 
been demonstrated that the NADPH oxidase system activity increased 
significantly in AP [49,50]. Oral consumption of dihydro-resveratrol has 
been shown to decrease, in a considerable amount, the NADPH oxidase 
Fig. 1. Resveratrol and its bioconversion.  
Fig. 2. Resveratrol and the factors it may possibly interact 
with in acute pancreatitis. Cyclooxygenase-2 (COX-2); Phos-
phoinositide 3-kinases (PI3Ks); Inducible nitric oxide synthase 
(iNOS); Endothelial nitric oxide synthase (eNOS); Nitric oxide 
(NO); MicroRNAs (miRNAs); Myeloperoxidase (MPO); Heat 
shock factor-1 (HSF-1); Sirtuin 1(SIRT1); Superoxide dismutase 
(SOD); Glutathione peroxidase (GSHPx); Reactive oxygen spe-
cies (ROS); B-cell lymphoma 2 (Bcl-2); Intercellular Adhesion 
Molecule (ICAM); vascular cell adhesion molecule (VCAM); 
Interleukins (ILs); Endothelin (ET); Tumor necrosis factor alpha 
(TNFα); 2,4-Dinitrophenylhydrazine (DNPH); nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB); 
Malondialdehyde (MDA).   
S. Agah et al.                                                                                                                                                                                                                                    
Biomedicine & Pharmacotherapy 137 (2021) 111268
3
function in pancreatic tissues [25,51]. Moreover, the anti-inflammatory 
impact of resveratrol on AP was further demonstrated by diminished 
Myeloperoxidase (MPO) function, which is a criteria of neutrophil 
degradation [52]. The effect of resveratrol on oxidative stress related 
elements are presented in Fig. 3. 
1.2. Effects of resveratrol on inflammatory mediators 
Immune response and inflammation play a crucial role in the path-
ophysiology of AP. Regarding immune functions, various inflammatory 
factors are recognized to be not only initiators of AP but also key agents 
in the progression of necrosis [53]. It has been shown that resveratrol 
Fig. 3. Effects of resveratrol on oxidative stress parameters. Resveratrol reduces damage of cellular membranes by decreasing lipid peroxidation. It improves the 
antioxidant defense system via GPx and SOD enzymes by increasing the expression of nuclear factor erythroid 2–related factor 2 (Nrf2). Resveratrol also decreases 
protein carbonylation through increased expression of SIRT1. Finally, resveratrol decreases oxidant factors and ROS via inhibition of NF-kB. 
Fig. 4. Effects of resveratrol on inflammatory parameters. Resveratrol inhibits leukocyte adhesion to pancreatic cells through suppression of ICAM and VCAM; 
Resveratrol inhibits TNF-alpha directly; it inhibits cell damage and decreases cell necrosis by suppression of NF-kB; Resveratrol increases IL-10 levels, which has anti- 
inflammatory properties; Resveratrol decreases pro-inflammatory prostaglandins through inhibition of Activator protein 1 (AP-1); Finally, resveratrol inhibits 
Phosphoinositide 3-kinases (PI3Ks) which are responsible for various inflammatory processes. 
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regulates proinflammatory cytokines [54]. Tumor necrosis factor alpha 
(TNF-α), which is secreted from polymorphonuclear neutrophils, lym-
phocytes and macrophages [55], is considered to be a “first-line” cyto-
kine [56]. TNF-α induces the generation of other pro-inflammatory 
factors and oxidant factors including ROS, and it also stimulates the 
oxidative stress-responsive genes that extend the chronic inflammatory 
response [57]. Furthermore, TNF-α synergistically impacts the genera-
tion of nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) and other cytokines related to inflammation [58]. NF-κB acti-
vated genes can induce cascade sequence-associated genes such as 
Interleukin 6 (IL-6), TNF-a, Interleukin-8 (IL-8), Interleukin-2 (IL-2), 
Intercellular Adhesion Molecule 1 (ICAM-1), etc [59]. Adhesion mole-
cules such as ICAM-1 and vascular cell adhesion molecule 1(VCAM-1) 
have a critical role in the activation of inflammatory response and 
leukocyte adherence [60]. Their gene expression is stimulated via in-
duction of inflammatory mediators, including TNF-α and IL-1 [61]. 
TNF-α modulates the gene expression of VCAM-1 and ICAM-1 in the 
gastrointestinal tract and regulates the adherence of monocytes, neu-
trophils, and lymphocytes to vascular endothelial cells. These cells, 
especially neutrophils, may cause damage to gastrointestinal endothelial 
cells through degranulation [62]. Recent findings show that adminis-
tration of resveratrol alleviates injuries to the intestinal mucosal barrier 
by inhibiting ICAM-1 and VCAM-1 surface gene expression [63,64]. In 
addition, it has been demonstrated that resveratrol is able to suppress 
the activation of the activator protein-1 (AP-1) [24] and NF-κB [65]. 
AP-1 is a major transcription element which modulates various cyto-
logical functions, such as oncogenic transformation, apoptosis, differ-
entiation, cell death, cell migration, and proliferation along with 
progression in various tissues [66]. Correspondingly, resveratrol has 
been shown to be related with a reduced level of IkappaB alpha (IκBα) 
degradation and suppression of AP-1 functions [67]. It has been shown 
that this suppression of NF-κB via resveratrol may be responsible for the 
inhibition of cell-mediated cytotoxicity and lymphocyte proliferation 
[68]. In the cytosol, inhibitor protein kappa B (IκB) bounds to NF-κB and 
deactivates it. After activation of IκB, specific IκB kinases phosphorylate 
IκB; afterwards, IκB is rapidly degraded through proteasome-dependent 
pathways [69]. It has been shown that resveratrol inhibits the activation 
of NF-κB by suppressing the degradation of IκB [70]. 
Furthermore, it has been indicated that increased positive signals of 
Phosphoinositide 3-kinases (PI3K p85) were reported in pancreatic tis-
sues, and the intensity of PI3K signals decreased after resveratrol 
administration [71]. Moreover, Akt (Protein Kinase B) phosphorylation 
was observed to be increased in AP tissues. It also diminished after 
resveratrol administration [25,72]. Besides, antioxidant factors 
including resveratrol have the capability to decrease the level of 
leukocyte transfer to damaged tissue by intervening with myeloperox-
idase function [73]. It seems that the immunomodulatory characteristics 
of resveratrol, could be more effective in amelioration of AP than inhi-
bition of inflammatory factors. 
Resveratrol administration does not only decrease inflammatory 
mediators but also increases anti-inflammatory cytokines. For example, 
some studies reported that resveratrol intervention upregulated the 
expression of IL-10 [74]. IL-10 is known to have anti-inflammatory 
properties due to its effect on the generation of pro-inflammatory cy-
tokines [75]. The effect of resveratrol on inflammatory factors is pre-
sented in Fig. 4. 
1.3. Effects of resveratrol on tissue damage due to AP 
Formation of pancreatic edema is one of the main histological 
criteria for pancreatic damage [76]. It has been shown that resveratrol 
administration significantly reduces pancreatic edema in experimental 
models [25]. Severe, end stage forms of AP are determined by the pro-
gression of parenchymal necrosis accompanied by systemic complica-
tions and leukocyte infiltration, all of which are related to a worsening of 
the clinical condition of the patient [77]. It has been shown that 
resveratrol reduces leukocyte infiltration, but it does not significantly 
alter tissue damage [18,78]. 
Severe forms of AP usually cause several systemic complications 
which even affect distant organs including the lungs, heart, brain, liver, 
kidneys, and bones [79]. Acute lung damage is regarded as one of the 
most recurrent potentially destructive complications of severe AP [80]. 
However, the pathogenesis of AP-related lung damage is still not totally 
understood, but it is probably related to an increase of pro-inflammatory 
cytokines in the lung. Recent findings indicate that oral consumption of 
resveratrol significantly improves AP-related general inflammatory re-
actions in the lungs through inhibition of the NF-κB signaling pathway 
and leads to a significant decrease of pro-inflammatory mediators [81]. 
Actually, pulmonary wall thickening, causing alveolar obstruction, is 
the most frequent histological feature of AP-associated systemic in-
flammatory damage [82]. Resveratrol administration, even at low doses 
such as 10 mg/kg body weight, is associated with improvement of pul-
monary wall thickening [81,83]. Amelioration of histological lung 
damage scores by administration of resveratrol is mainly related to 
inhibitory effects of resveratrol on the generation of different 
pro-inflammatory mediators such as, IL-6, IL-1β and TNF-α [84]. 
Heart failure is another cause of death in AP patients [85]. Micro-
circulation disturbance plays a crucial role in chronic heart complica-
tions [86]. Previous investigations have shown that microcirculatory 
disturbance also has a pivotal role of in the pathogenesis of AP [87]. 
Based on recent findings, it can be proposed that resveratrol adminis-
tration reduces microcirculatory disturbance and suppresses necrotic 
cell death during AP [88]. Experimental studies suggest several mech-
anisms for the effect of resveratrol on microcirculatory disturbance, 
including a decrease of edema and inflammation via down-regulation of 
Apoptosis regulator BAX (Bax) and caspase 3 and upregulation of Bcl-2 
[89]. Moreover, resveratrol diminishes gene expression of cytochrome C 
and keeps cells safe from injuries [90,91]. 
Previous studies report that plasma renin activity and Angiotensin II 
(Ang II) concentrations rise during the progression of AP. It has been 
demonstrated that the renin–angiotensin system has a crucial role in the 
initiation of AP [26], and Ang II, plasma endothelin (ET), and NO are 
up-regulated during AP [92]. In addition to beneficial role of resveratrol 
on microcirculatory disturbance, investigators show that resveratrol 
administration improves plasma renin activity and down-regulates 
plasma ET, Ang II, and NO [88]. Researchers propose that plasma 
levels of ET and NO are increased in initial stages of AP and change the 
amount of blood flow in local pancreatic vessels. Altogether, these al-
terations cause hypoxia, hemodynamic instability, tissue ischemia, and 
finally, advanced AP [93]. Elevated concentration of ET upregulate 
intracellular calcium and increase the function of pro-inflammatory cells 
[94]. Plasma concentration of NO is also elevated because of increased 
NOS-activity [95]. Resveratrol administration is likely to diminish 
concentrations of ET and NO via suppression of ET receptors and NOS 
[96]. Previous investigations proposed that resveratrol suppresses the 
expression of iNOS and decreases inflammation and pancreatic tissue 
injury [97]. 
It has been shown that, Resveratrol also can improve the efficacy and 
therapeutic effects of other treatment approaches for AP. For example 
Bone marrow-derived mesenchymal stem cells (BMSCs) are recently 
proposed to treatment of AP [98]. It has been demonstrated that 
resveratrol pretreatment of BMSCs (Res-BMSCs) improve the therapeu-
tic impact of decreasing apoptosis of pancreatic cells and increase 
regeneration of damaged blood vessels [71]. 
1.4. Resveratrol and enzymes in AP 
Hyperlipidemia and hyperamylasemia are typical features of initial 
early-stage AP [99]. Indeed, these features are often used for the diag-
nosis of AP [100]. Recent findings shed light on the role of resveratrol 
supplementation concerning premature activation of pancreatic en-
zymes [52]. Increased α-amylase is a primary diagnostic criterion for AP 
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[101]. Although amylase and lipase enzymes often increase threefold in 
AP patients, there seems to be no association between the severity of AP 
and serum levels of these enzymes [102]. However, it has been reported 
that resveratrol administration can reduce levels of serum amylase and 
lipase in AP patients [20,25,29]. Moreover, recent experimental studies 
indicate that intervention with resveratrol was not enough to suppress 
tissue damage, although amylase and lipase serum concentrations 
decreased [67]. As serum amylase concentration is the main biomarker 
for AP, serum Lactate dehydrogenase (LDH) activity could represent the 
amount of necrosis [103] and MPO function is associated with neutro-
phil recruitment [104]. Serum pancreatic MPO and LDH activity are 
remarkably elevated in AP. Resveratrol diminishes pancreatic MPO ac-
tivity and serum LDH activity in rat AP-models [105]. 
Trypsin activation due to pro-inflammatory cytokine-release is 
recognized to be another initial mechanism in AP-mediated tissue 
damage [106,107]. However, experimental studies show that resvera-
trol does not suppress trypsin activity [67]. 
1.5. Resveratrol and gene expression in AP 
mRNA gene expression of inflammatory mediators such as IL-6, TNF- 
α, IL-10 is thought to change in AP patients [108]. Resveratrol was found 
not only to significantly diminish pancreatic IL-6 and TNF-α mRNA 
expression, but it also increases pancreatic IL-10 mRNA expression 
[105]. Sirtuin 1 (SIRT1) is a NAD dependent deacetylase that modulates 
cell proliferation, metabolism, and DNA repair and acts as a modulator 
for several cellular antioxidant processes [109]. Recent findings show 
that SIRT1 modulates the expression of specific glucose sensing and 
insulin secretion in the pancreas through mitochondria-related genes 
that control metabolic coupling [110]. Resveratrol was found to be a 
classic SITR1 stimulator [111], and it has been shown that resveratrol 
protects pancreatic cells by increased expression of SITR1 [112,113]. 
Overexpression of SIRT1gene seems to protect pancreatic β-cells from 
toxicity from inflammatory mediators by inhibiting the NF-κB signaling 
pathway [114]. It has been shown that resveratrol also protects 
pancreatic β-cells by augmenting SIRT1 [115]. 
P53 is a pro-apoptotic protein which is strongly associated with 
SIRT1. p53 expression was remarkably decreased in the pancreas of rats 
with AP [116], and resveratrol increased p53 expression significantly 
[117]. Moreover, HSF1, which is one of the main heat shock transcrip-
tion elements, is expressed widely in different kind of cells and has a 
pivotal role in inflammation by modulating the transcription of relevant 
cytokines and inflammatory mediators [118–120]. Acetylation of HSF1 
diminishes its DNA attachment function and thereby increases tran-
scription of pro-inflammatory mediators and suppresses transcription of 
anti-inflammatory elements. It has been shown that HSF1-knockout 
mice with pancreatitis induced by cerulein experienced acute edema 
that was more severe than in control mice [83]. It has been demon-
strated that HSF1 expression was remarkably reduced in pancreatic 
tissues of AP mice, indicating that HSF1 has a role in the pathogenesis of 
AP. Resveratrol does not only increase the total expression of HSF1, but 
resveratrol administration also decreases acetylated HSF1 [105]. 
In addition, resveratrol exerts its protective effects against AP 
through microRNA (miRNA) modification. It seems that resveratrol 
exerts its antitumor and anti-inflammatory effects through modulation 
of the expression of specific miRNAs [121]. For instance, the expression 
level of miR-126 was upregulated by administration of resveratrol 
[122]. miR-126 suppresses inflammation and inflammatory mediators 
in endothelial cells [123]. Resveratrol changes miR-126 expression 
through upregulation of KLF2. KLF2 is a zinc-finger family’s transcrip-
tion factor; a crucial regulator in the progress of cell development and 
differentiation [124]. miR-21 is a necessary element for ROS-promoted 
pancreatic stellate cell function, and decrease in miR-21 interrupts 
ROS-promoted migration in pancreatic stellate cells [125]. Resveratrol 
was found to suppress pancreatic cancer cell migration and invasion via 
inhibition of glycolysis in pancreatic stellate cells and 
ROS/miR-21-mediated function [126]. Resveratrol also diminishes the 
expression of miR-21 and inhibits BCL-2 expression and thereby protects 
pancreatic cells from necrosis [127]. 
Fig. 5. Resveratrol decreases damage to pancreatic tissue through suppression of calcium overload; it suppresses calcium overload and thereby decreases trypsinogen 
activation, oxidative stress, mitochondrial dysfunction and microcirculatory disorders; Resveratrol also decreases damage to other organs including lung and heart by 
decreasing microcirculatory dysfunction. 
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1.6. Effects of resveratrol on calcium overload 
Several triggers have been recognized to be involved in the etiology 
of AP, but exact mechanisms are still poorly understood. Free calcium 
ions inside the cytoplasm of acinar cells function as a main second 
messenger. Calcium overload may have pivotal role in the pathogenesis 
of AP [128]. Calcium signaling pathways have been shown to be 
disturbed in initial stages of AP [129]. Under normal and healthy cir-
cumstances, calcium concentrations are stable, while in pathological 
situations, several factors can impact intracellular calcium concentra-
tions and may lead to a rise in intracellular calcium levels causing a 
calcium overload [130]. This may be true for AP as well [131]. Recent 
research shows that calcium overload is not only an etiological indicator 
for AP, it also worsens the condition by effects on other organs and or-
ganelles [129]. It has been shown that cytoplasmic calcium overload 
causes disfunction of acinar cell secretion, increased activation of 
trypsinogen, early activation of zymogens, cell necrosis, oxidative stress, 
microcirculatory dysfunctions, and mitochondrial disorders [128]. 
Intracellular calcium overload is also associated with severe lung tissue 
damage in AP patients. Resveratrol administration can efficiently 
decrease the complications of AP by regulating intracellular 
calcium-modulatory pathways and by decreasing calcium overload 
[132]. The effect of resveratrol on calcium overload and tissue damage is 
presented in Fig. 5. 
2. Conclusions 
Acute pancreatitis is a common, severe and potentially life- 
threatening acute gastrointestinal disease. Recent evidence suggests 
that resveratrol might be a useful tool in the management of AP. 
Resveratrol might alleviate pancreatic damage and damage in other 
organs through various pathways. It seems to suppress NF-κB activity 
and regulate the generation of inflammatory mediators, and it improves 
the anti-oxidative defense system, modulates and manages intracellular 
calcium in pancreatic acinar cells and modulates the expression of 
several genes and transcriptional factors that are related to the patho-
physiology of AP. To sum up, resveratrol seems to have several benefi-
cial effects on AP, but high-quality trials in humans are needed to 
underpin these findings. 
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